Margaret Macro

Margaret Macro

UNVERIFIED PROFILE

Are you Margaret Macro?   Register this Author

Register author
Margaret Macro

Margaret Macro

Publications by authors named "Margaret Macro"

Are you Margaret Macro?   Register this Author

46Publications

2571Reads

32Profile Views

Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.

Leukemia 2019 Sep 9;33(9):2324-2330. Epub 2019 Apr 9.

ProfilExpert, Lyon, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0452-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6756025PMC
September 2019

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med 2019 05;380(22):2104-2115

From University of Lille, Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille (T.F.), Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.), Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac (C.H.), Hematology Department, University Hospital, Vandoeuvre lès Nancy (A.P.), Service d'Hématologie, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (M.A.), Department of Hematology, Vendée Hospital, La Roche sur Yon (M.T.), CHU de Caen, Caen (M.M.), Department of Clinical Hematology, Assistance Publique-Hôpitaux de Paris, Necker Hospital, Paris (L.F.), and Department of Hematology, CHU la Miletrie and INSERM CIC 1402, Poitiers (X.L.) - all in France; the Department of Hematology, Mayo Clinic Rochester, Rochester, MN (S.K.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.); Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); University of Calgary, Arnie Charbonneau Cancer Research Institute, Calgary, AB (N.B.), and the Division of Medical Oncology, University of Alberta, Edmonton (C.P.V.) - both in Canada; Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom (S.B.); Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); University of Melbourne, St. Vincent's Hospital, Melbourne, VIC, Australia (H.Q.); University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg (H.G.), and the Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg (K.W.) - both in Germany; Department of Medicine-Haematology, National University of Ireland, Galway (M.O.); Florida Cancer Specialists and Research Institute, St. Petersburg (J.R.M.); the Department of Hematology-Oncology, Massachusetts General Hospital, Boston (N.R.); Genmab US, Princeton (T.A.), and Janssen Research and Development, Raritan (J.W., R.K.) - both in New Jersey; Janssen Research and Development, Spring House, PA (C.C., C.M.U., M.Q.); Janssen Research and Development, Beerse, Belgium (R.V.R.); and Levine Cancer Institute-Atrium Health, Charlotte, NC (S.Z.U.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1817249
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1817249DOI Listing
May 2019

Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.

J Clin Oncol 2017 Sep 7;35(25):2911-2918. Epub 2017 Jul 7.

Philippe Moreau, Florence Caillon, Caroline Bodet-Milin, Aurelie Gaultier, Jean-Michel Nguyen, Benoit Dupas, Eric Frampas, and Françoise Kraeber-Bodere, University Hospital, Nantes; Michel Attal, University Hospital, Toulouse; Denis Caillot, University Hospital, Dijon; Margaret Macro, University Hospital, Caen; Lionel Karlin, University Hospital, Lyon; Laurent Garderet, University Hospital Saint-Antoine, Paris; Thierry Facon, University Hospital, Lille; Lotfi Benboubker, University Hospital, Tours; Martine Escoffre-Barbe, University Hospital, Rennes; Anne-Marie Stoppa, Institut Paoli-Calmettes, Marseille; Kamel Laribi, University Hospital, Le Mans; Cyrille Hulin and Gerald Marit, University Hospital, Bordeaux; Aurore Perrot, University Hospital, Nancy; Jean-Richard Eveillard, University Hospital, Brest; Brigitte Pegourie, University Hospital, Grenoble; Veronique Dorvaux, University Hospital, Metz; Carine Chaleteix, University Hospital, Clermont-Ferrand; and Herve Avet-Loiseau, University Hospital, Toulouse, France; and Kenneth Anderson, Paul Richardson, and Nikhil C. Munshi, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.2975DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578392PMC
September 2017

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

N Engl J Med 2017 04;376(14):1311-1320

From the Institut Universitaire du Cancer de Toulouse-Oncopole (M.A., M.R., C.P., S.R., H.A.-L.) and Service d'Epidémiologie, Centre Hospitalier et Universitaire de Toulouse (V.L.-C.), Toulouse, Hôpital Haut-Lévêque, Bordeaux Pessac (C.H.), Centre Hospitalier et Universitaire la Miletrie, Poitiers (X.L.), Centre Hospitalier Le Bocage, Dijon (D.C.), Centre Hospitalier et Universitaire de Rennes, Rennes (M.E.), Hôpital St.-Louis (B.A., J.P.F.), Centre Hospitalier Universitaire, Hôpital St.-Antoine (L.G.), Institut Curie (C.M.), and Haute Autorité de Santé (J.-L.H.), Paris, Institut d'Hématologie de Basse Normandie, Centre Hospitalier et Universitaire de Caen, Caen (M.M.), Centre Hospitalier et Universitaire Henri Mondor, Creteil (K.B.), Hôpital Claude Huriez, Lille (T.F.), and Hôtel Dieu, Nantes (P.M.) - all in France; Institut Jules Bordet, Brussels (N. Meuleman); and Dana-Farber Cancer Institute, Boston (M.E.M., A.A.Z., E.A.W., N. Munshi, K.C.A., P.G.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611750DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201242PMC
April 2017

Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial.

J Clin Oncol 2016 10;34(30):3609-3617

Cyrille Hulin, Bordeaux Hospital University Center, Bourdeaux; Philippe Rodon, Centre Hospitalier de Périgueux, Périgueux; Brigitte Pégourié, Centre Hospitalier Regional Universitaire, Grenoble; Laurent Garderet, Centre Hospitalier Universitaire (CHU) Hôpital St-Antoine, Paris; Isabelle Azais, CHU Institut National de la Santé et de la Recherche Médicale (INSERM); Xavier Leleu, Hôpital de la Milétrie, CHU INSERM, Poitiers; Margaret Macro, CHU de Caen, Caen; Bruno Royer, University Hospital, Amiens; Thierry Facon, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Andrew Belch, Cross Cancer Institute, Edmonton, Alberta; Chaim Shustik, Royal Victoria Hospital; Richard LeBlanc, Hôpital Maisonneuve-Rosemont, Montreal, Quebec; Kevin Song, Vancouver General Hospital, Vancouver, British Columbia, Canada; Maria Teresa Petrucci, Azienda Policlinico Umberto I, University La Sapienza, Rome, Italy; Ulrich Dührsen, University Hospital of Essen, West German Cancer Center, Essen, Germany; Jin Lu, Peking University Institute of Hematology, People's Hospital, Beijing, China; Hannah Hunter, Derriford Hospital, Plymouth, United Kingdom; Richard Eek, Border Medical Oncology, Wodonga, Victoria, Australia; Heinz Gisslinger, Medizinische Universität Wien, Vienna, Austria; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Cristina Goncalves, Hospital de Santo Antonio-Porto, Porto, Portugal; Ken Romeril, Wellington Hospital, Wellington, New Zealand; Chantal Doyen, Université Catholique de Louvain (UCL), CHU UCL Namur, Yvoir; Fritz Offner, Universitair Ziekenhuis Gent, Ghent, Belgium; Nicolas Leupin, Celgene International, Boudry, Switzerland; Vanessa Houck, Guang Chen, and Annette Ervin-Haynes, Celgene, Summit, NJ; and Meletios A. Dimopoulos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.7295DOI Listing
October 2016

Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.

J Clin Oncol 2016 06 25;34(18):2125-32. Epub 2016 Apr 25.

Bruno Royer, Momar Diouf, and Jean Pierre Marolleau, University Hospital, Amiens; Stéphane Minvielle and Philippe Moreau, University Hospital; Stéphane Minvielle, Institut National de la Santé et de la Recherche Médicale U892, Nantes; Murielle Roussel and Hervé Avet-Loiseau, Institute Universitaire du Cancer de Toulouse Oncopole; Hervé Avet-Loiseau, University Hospital, Toulouse; Lionel Karlin, University Hospital, Lyon; Cyrille Hulin, University Hospital, Vandœuvre lès Nancy; Bertrand Arnulf, St Louis University Hospital; Laurent Frenzel, Necker University Hospital; Laurent Garderet, St Antoine University Hospital; Sylvain Choquet, La Pitié University Hospital, Paris; Margaret Macro, University Hospital, Caen; Sylvie Cailleres, General Hospital, Aix en Provence; Annie Brion, University Hospital, Besançon; Sabine Brechignac, University Hospital, Bobigny; Karim Belhadj, University Hospital, Creteil; Marie Lorraine Chretien, University Hospital, Dijon; Marc Wetterwald, General Hospital, Dunkerque; Carine Chaleteix, University Hospital, Clermont-Ferrand; Mourad Tiab, General Hospital, La Roche/Yon; Xavier Leleu, University Hospital, Poitiers; Jean Gabriel Fuzibet, University Department, Nice; Charles Dauriac, University Hospital, Rennes; Luc-Matthieu Forneker, University Hospital, Strasbourg; Lotfi Benboubker, University Hospital, Tours; and Thierry Facon, University Hospital, Lille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.1929DOI Listing
June 2016

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.

Haematologica 2015 Nov 23;100(11):e471-4. Epub 2015 Jul 23.

Immuno-Hematology, Saint-Louis Hospital, Paris, France Université Paris Diderot, Sorbonne Paris Cité, Paris, France INSERM UMR 1126 Institut Universitaire d'Hématologie, Paris, France

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2015.127001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825293PMC
November 2015

Epidemiology of Monoclonal Gammopathy of Undetermined Significance (MGUS): The experience from the specialized registry of hematologic malignancies of Basse-Normandie (France).

Cancer Epidemiol 2014 Aug 29;38(4):354-6. Epub 2014 May 29.

Service d'Hématologie Clinique, CHU de Caen, 14000 Caen, France; Laboratoire d'Hématologie, CHU de Caen, 14000 Caen, France; Registre Régional des Hémopathies Malignes de Basse-Normandie, CHU de Caen, 14000 Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canep.2014.04.006DOI Listing
August 2014

AL amyloidosis with temporal artery involvement simulates giant-cell arteritis.

Joint Bone Spine 2012 Mar 28;79(2):195-7. Epub 2011 Dec 28.

Department of Internal Medicine, CHU de Caen, 14000 Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jbspin.2011.09.007DOI Listing
March 2012

IgM multiple myeloma: more on a rare and heterogeneous disease.

Am J Hematol 2011 Aug 31;86(8):717-8; author reply 718-9. Epub 2011 May 31.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.22067DOI Listing
August 2011

Hematogones: a new prognostic factor for acute myeloblastic leukemia.

Blood 2011 Jan 15;117(4):1315-8. Epub 2010 Nov 15.

Service d'Hématologie Clinique, Centre Hospitalier Universitaire, Côte de Nacre, Caen Cedex, France.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2010-07-29
Publisher Site
http://dx.doi.org/10.1182/blood-2010-07-295378DOI Listing
January 2011

[Monoclonal gammopathies].

Authors:
Margaret Macro

Rev Prat 2008 Nov;58(18):2071-7

Service d'hématologie clinique, centre hospitalier universitaire 14033 Caen Cedex, France.

View Article

Download full-text PDF

Source
November 2008

Skin manifestations in CD4+, CD56+ malignancies.

Eur J Dermatol 2003 Mar-Apr;13(2):161-5

Department of Dermatology, Centre Hospitalier Universitaire, Avenue Georges Clemenceau, 14033 Caen Cedex, France.

View Article

Download full-text PDF

Source
July 2003